LMDXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (5 4月 2024 @ 05:00):

Stats
本日の出来高	120.55M
平均出来高	0.00
時価総額	249.63M
EPS	$0 ( 2024-03-19 )
次の収益日	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.0140 (93.33%)

ボリューム相関

長: 0.04 (neutral)

短: -0.37 (neutral)

Signal:(34.365) Neutral

LumiraDx Limited 相関

10 最も正の相関
OZK	0.892
DDIV	0.888
PNFP	0.881
FTXO	0.88
PSCF	0.879
COLB	0.879
FITB	0.877
UG	0.877
ARQT	0.874
AIRG	0.87

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

LumiraDx Limited 相関 - 通貨/商品

0.27
( neutral )

-0.56
( weak negative )

0.00
( neutral )

-0.11
( neutral )

0.58
( weak )

-0.36
( neutral )

LumiraDx Limited 財務諸表

Annual	2022
収益:	$254.48M
総利益:	$-35.30M (-13.87 %)
EPS:	$-1.590

FY	2022
収益:	$254.48M
総利益:	$-35.30M (-13.87 %)
EPS:	$-1.590

Financial Reports:

No articles found.

LumiraDx Limited

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.